Quick Takeaways
- ARMISTICE CAPITAL, LLC filed SCHEDULE 13G/A for XORTX Therapeutics Inc. Common shares, no par value per share (XRTX).
- Disclosed ownership: 5%.
- Date of event: 31 Mar 2025.
ARMISTICE CAPITAL, LLC - 31 Mar 2025 SCHEDULE 13G/A Report for XORTX Therapeutics Inc. Common shares, no par value per share (XRTX)
- Filing Manager
- ARMISTICE CAPITAL, LLC
- Reporting Manager
- Armistice Capital, LLC
- Symbol
- XRTX
- Shares outstanding
- 3,567,756 shares
- Disclosed Ownership
- 178,031 shares
- Ownership
- 5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 15:14:32 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ARMISTICE CAPITAL, LLC disclosed 5% ownership in XORTX Therapeutics Inc. Common shares, no par value per share (XRTX) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 15 May 2025, 15:14.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 5% | 178,031 | 0 | 178,031 | /s/ Steven Boyd | Steven Boyd - Managing Member | |
| Steven Boyd | 5% | 178,031 | 0 | 178,031 | /s/ Steven Boyd | Steven Boyd |